この論文をさがす
説明
To the Editor: Thirty-eight patients with Mycobacterium bovis BCG–associated osteomyelitis/osteitis, including 8 who were previously reported (1), were identified during Taiwan’s vaccine injury compensation program during 1989–2012; a total of 30 (79%) patients applied for compensation during 2009–2012 (Figure). In Taiwan, a laboratory program to differentiate BCG from other species of the M. tuberculosis complex, using a kit for the Tokyo-172 vaccine strain spoligotyping, was established in 2004 (1). Since 2008, the isolated extrapulmonary tuberculosis strains and pathologic specimens collected from children <5 years of age have been sent to the national reference mycobacterial laboratory for BCG detection (2). The detected incidence of BCG osteitis/osteomyelitis increased from 3.68 cases per million vaccinations during 2002–2006 to 30.1 per million during 2008–2012.
収録刊行物
-
- Emerging Infectious Diseases
-
Emerging Infectious Diseases 21 539-540, 2015-03-01
Centers for Disease Control and Prevention (CDC)
- Tweet
キーワード
- osteitis
- tuberculosis and other mycobacterial infections
- Mycobacterium bovis BCG
- Incidence
- vaccine injury compensation program
- R
- Infant, Newborn
- Taiwan
- osteomyelitis
- Infant
- Osteomyelitis
- Infectious and parasitic diseases
- RC109-216
- Child, Preschool
- BCG Vaccine
- Medicine
- Humans
- Tuberculosis
- Letters to the Editor
